Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2014

View Archived Issues

Full year report - 2013 was a successful year for Lundbeck

Technetium Tc 99m trofolastat accurately detects cancer in the prostate gland

Takeda Pharmaceutical advances key programs in third quarter of fiscal 2013

ARADES and ARAFOR trial data reported for ODM-201 in prostate cancer

Protalex reports data from phase Ib trial of PRTX-100 in active rheumatoid arthritis

arGEN-X begins phase Ib study of ARGX-111

GlaxoSmithKline reports discovery of selective androgen receptor modulators

First-in-human clinical evaluation of a sustained-release exenatide for the treatment of diabetes

Ganymed Pharmaceuticals begins phase I/II trial of IMAB-027 in advanced ovarian cancer

Merck & Co. discloses new HIV prodrugs

Regeneron Pharmaceuticals and Bayer HealthCare report 2-year data from VISTA-DME trial

New targeted immunotherapy compounds designed by Shanghai Birdie Biotech

EMA's Committee for Orphan Medicinal Products issues positive opinion on Arikace

Biogen Idec patent divulges novel S1P modulating agents

Merck & Co. reports development of DPP IV inhibitors for diabetes

Sarepta Therapeutics reports safety data from phase I study of AVI-7288

Study of Repros' Androxal shows sustained effect in men with secondary hypogonadism

Aduro BioTech begins phase IIb ECLIPSE trial in patients with pancreatic cancer

Audion Therapeutics and Lilly to develop hearing loss treatments

Results from preliminary safety study evaluating trebananib plus abiraterone in patients with CRPC

Gilead submits NDA for fixed-dose combination tablet for HCV infection

Lipocine begins dosing in pivotal SOAR study

Oramed submits phase IIa protocol to FDA for oral insulin capsule

Scancell's SCIB-1 receives FDA orphan drug status for metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...